Selected article for: "cell surface and CoV infect"
Author: Min Cao; Dandan Zhang; Youhua Wang; Yunfei Lu; Xiangdong Zhu; Ying Li; Honghao Xue; Yunxiao Lin; Min Zhang; Yiguo Sun; Zongguo Yang; Jia Shi; Yi Wang; Chang Zhou; Yidan Dong; Ping Liu; Steven M Dudek; Zhen Xiao; Hongzhou Lu; Longping Peng
Title: Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China
  • Document date: 2020_3_6
    • ID: dmud2zf7_47
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 In addition, we observed a marked reduction in T and T H subtype cells in infected patients, suggesting that SARS-Cov-2 infection may impair cellular immunity. It is known that MERS-CoV is able to infect both CD4 + and CD8 + primary human T cells and, upon infection induces T cell apoptosis in vitro 7 . While the cell surface receptor.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org /10.1101 /10. /2020 In addition, we observed a marked reduction in T and T H subtype cells in infected patients, suggesting that SARS-Cov-2 infection may impair cellular immunity. It is known that MERS-CoV is able to infect both CD4 + and CD8 + primary human T cells and, upon infection induces T cell apoptosis in vitro 7 . While the cell surface receptor for SARS-Cov-2 has now been identified as ACE2 8 , other receptors may also exist on immune cells to bind to coronavirus [9] [10] [11] . As there is no proven antiviral treatment yet available, strategies to enhance the immune system may be considered. Since the most common haematological changes in COVID-19 patients were lymphopenia and immunodeficiency, we postulate that hematopoietic growth factors such as G-CSF, by mobilizing endogenous blood stem cells and endogenous cytokines, may represent a potential haematological treatment for COVID-19 patients 12 .

    Search related documents:
    Co phrase search for related documents
    • antiviral treatment and blood stem: 1, 2, 3
    • antiviral treatment and blood stem cell: 1
    • antiviral treatment and cell apoptosis: 1, 2, 3
    • antiviral treatment and cell surface: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral treatment and cell surface receptor: 1
    • antiviral treatment and cellular immunity: 1
    • antiviral treatment and growth factor: 1, 2
    • antiviral treatment and immune cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • available antiviral treatment and cell surface: 1
    • available antiviral treatment and cell surface receptor: 1
    • blood stem and cell surface: 1, 2
    • blood stem and immune cell: 1, 2, 3, 4, 5
    • blood stem cell and immune cell: 1, 2, 3, 4
    • cell apoptosis and growth factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell apoptosis and immune cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell surface and endogenous cytokine: 1
    • cell surface and growth factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell surface and immune cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell surface receptor and endogenous cytokine: 1